Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB ...

Clinical trial results found that a majority of patients with atopic dermatitis who were treated with Ebgylss achieved ...

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses the promising results of DB-OTO in the CHORD trial for children with otoferlin-related hearing loss.

In regard to what’s happening now with NIH, the main thing to do is diversify. You raise both non-dilutive funding through NIH which is the very best, obviously, and then as well as dilutive and to ...

HEOR scientists in the pharma industry must balance methodologic rigor with commercial expectations and timelines.

Self-service data analytics company Gigasheet announced a new digital platform designed to enhance healthcare price ...

The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...

Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance ...

The six key design trends of 2025 redefine how healthcare brands can inspire trust and build lasting connections with their ...

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, describes how his company's ...

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack ...

The acquisition is expected to enhance Jazz's oncology portfolio by adding dordaviprone, a novel small molecule therapy in ...